Sign in or create an account to add this stock to your watchlist.
About Horizon Pharma (NASDAQ:HZNP)
Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients. Its products also include KRYSTEXXA to treat chronic refractory gout; RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus, and various other indications; PENNSAID 2% to treat pain of osteoarthritis of the knees; DUEXIS for the treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis; VIMOVO to treat signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis; and MIGERGOT for the treatment of vascular headache. The company has collaboration agreement with Fox Chase Cancer Center to evaluate ACTIMMUNE in combination with PD-1/PD-L1 inhibitors in various forms of cancer; Alliance for Lupus Research to evaluate RAYOS/LODOTRA on the fatigue experienced by systemic lupus erythematosus patients; and Syneos Health, Inc. in connection with its Phase III confirmatory trial to evaluate teprotumumab for the treatment of thyroid eye disease. Horizon Pharma Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:HZNP
CUSIP44047T10
Phone011-353-1772-2100
Debt
Debt-to-Equity Ratio2.17
Current Ratio1.56
Quick Ratio1.50
Price-To-Earnings
Trailing P/E Ratio12.84
Forward P/E Ratio10.74
P/E Growth0.89
Sales & Book Value
Annual Sales$1.06 billion
Price / Sales2.40
Cash Flow$3.1220 per share
Price / Cash4.92
Book Value$5.22 per share
Price / Book2.94
Profitability
EPS (Most Recent Fiscal Year)$1.18
Net Income$-410,520,000.00
Net Margins-45.06%
Return on Equity16.97%
Return on Assets3.99%
Miscellaneous
Employees1,010
Outstanding Shares165,040,000
Horizon Pharma (NASDAQ:HZNP) Frequently Asked Questions
What is Horizon Pharma's stock symbol?
Horizon Pharma trades on the NASDAQ under the ticker symbol "HZNP."
How will Horizon Pharma's stock buyback program work?
Horizon Pharma declared that its Board of Directors has initiated a stock buyback program on Sunday, June 4th 2017, which allows the company to repurchase 1,000% of shares, according to EventVestor. This repurchase authorization allows the company to repurchase shares of its stock through open market purchases. Stock repurchase programs are often an indication that the company's board of directors believes its shares are undervalued.
How were Horizon Pharma's earnings last quarter?
Horizon Pharma PLC (NASDAQ:HZNP) released its quarterly earnings results on Wednesday, May, 9th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by $0.08. The biopharmaceutical company earned $223.88 million during the quarter, compared to the consensus estimate of $232.05 million. Horizon Pharma had a positive return on equity of 16.97% and a negative net margin of 45.06%. The firm's revenue was up 1.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.21 EPS. View Horizon Pharma's Earnings History.
When is Horizon Pharma's next earnings date?
What price target have analysts set for HZNP?
10 Wall Street analysts have issued twelve-month price targets for Horizon Pharma's stock. Their forecasts range from $16.00 to $24.00. On average, they expect Horizon Pharma's share price to reach $19.20 in the next year. View Analyst Ratings for Horizon Pharma.
What are Wall Street analysts saying about Horizon Pharma stock?
Here are some recent quotes from research analysts about Horizon Pharma stock:
- 1. Mizuho analysts commented, "We Think Raised Guidance is Possible Once 340B Delay is Official; Reiterate Buy Rating Buy Previous Rating No Change Price (5/04) $14.24 Price Target $18.00 Previous Price Target No Change 340B Rule delay may not be entirely surprising, but still positive: The Department of Health and Human Services (HHS) proposed to further delay the effective date of the 340B drug pricing program from July 1, 2018, to July 1, 2019. Mgmt. expects an official decision on this delay within a few days or weeks after Memorial Day (May 28). Because the delay will not be finalized before Horizon’s May 9 earnings call, we think the company may not raise guidance this week, but could discuss a range of potential upside estimates on its call. The company’s current revenue guidance is $1.15B-$1.18B. We think there is some investor trepidation about seasonal weakness into the print that could improve due to this update. We reiterate our Buy rating and note our model does not yet include this upside." (5/7/2018)
- 2. According to Zacks Investment Research, "Horizon Pharma’s orphan and rheumatology business units have continued to show strong growth. We expect Krystexxa, Ravicti and Actimmune to drive further growth. The acquisition of teprotumumab has further diversified the company’s portfolio. However, revenues from primary care business units declined due to the implementation of a new commercial model where the company is contracting with pharmacy benefit managers and payers to help patients obtain access to its medicines. Moreover, in June 2017, Horizon Pharma sold the marketing rights for Procysbi and Quinsair in the Europe, the Middle East and Africa regions to Chiesi Farmaceutici S.p.A. as the company focuses on higher-return businesses. Shares of the company have outperformed the industry in the past six months. Estimates have remained stable ahead of the Q1 earnings results. The company has a mixed record of earnings surprises in recent quarters." (5/4/2018)
- 3. Cantor Fitzgerald analysts commented, "Message in a bottle/vial. The four doctors we spoke with were positive on the safety and efficacy of Horizon’s Krystexxa. One of the four doctors believed that Krystexxa was a ‘wonder’ drug and was bullish on its growth prospects. The other three doctors were more measured. They all agreed that Krystexxa is a very good drug, but were not convinced it would be widely used among rheumatologists because it works best for a small group of refractory patients. The main barrier to uptake is not anaphylaxis. There are two reasons doctors don’t widely use Krystexxa: 1) the high cost relative to standard of care; 2) because it’s an IV, while the standard of care is oral." (3/14/2018)
Who are some of Horizon Pharma's key competitors?
Some companies that are related to Horizon Pharma include Valeant Pharmaceuticals Intl (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Catalent (CTLT), GALAPAGOS NV/S (GLPG), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO), Dr. Reddy's Laboratories (RDY), United Therapeutics (UTHR), Taro Pharmaceutical Industries (TARO), Hutchison China MediTech (HCM), FibroGen (FGEN) and GW Pharmaceuticals (GWPH).
Who are Horizon Pharma's key executives?
Horizon Pharma's management team includes the folowing people:
- Mr. Timothy P. Walbert, Chairman, Pres & CEO (Age 51)
- Mr. Paul W. Hoelscher, Exec. VP & CFO (Age 53)
- Mr. Barry J. Moze, Exec. VP & Chief Admin. Officer (Age 64)
- Ms. Irina Konstantinovsky, Exec. VP & Chief HR Officer (Age 48)
- Mr. Miles W. McHugh, Chief Accounting Officer and Sr. VP (Age 53)
Has Horizon Pharma been receiving favorable news coverage?
Media headlines about HZNP stock have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Horizon Pharma earned a news sentiment score of 0.19 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 46.61 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are Horizon Pharma's major shareholders?
Horizon Pharma's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Scopia Capital Management LP (9.19%), BlackRock Inc. (7.85%), Dimensional Fund Advisors LP (3.71%), venBio Select Advisor LLC (3.13%), JPMorgan Chase & Co. (2.14%) and Northern Trust Corp (1.19%). Company insiders that own Horizon Pharma stock include Jeffrey W Sherman, Michael G Grey, Robert Carey and Virinder Nohria. View Institutional Ownership Trends for Horizon Pharma.
Which major investors are selling Horizon Pharma stock?
HZNP stock was sold by a variety of institutional investors in the last quarter, including Scopia Capital Management LP, Dimensional Fund Advisors LP, BlackRock Inc., JPMorgan Chase & Co., Guggenheim Capital LLC, UBS Group AG, C WorldWide Group Holding A S and SG Americas Securities LLC. View Insider Buying and Selling for Horizon Pharma.
Which major investors are buying Horizon Pharma stock?
HZNP stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Millennium Management LLC, venBio Select Advisor LLC, American Century Companies Inc., Federated Investors Inc. PA, Russell Investments Group Ltd., Prudential Financial Inc. and Wells Fargo & Company MN. View Insider Buying and Selling for Horizon Pharma.
How do I buy shares of Horizon Pharma?
Shares of HZNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Horizon Pharma's stock price today?
One share of HZNP stock can currently be purchased for approximately $15.36.
How big of a company is Horizon Pharma?
Horizon Pharma has a market capitalization of $2.48 billion and generates $1.06 billion in revenue each year. The biopharmaceutical company earns $-410,520,000.00 in net income (profit) each year or $1.18 on an earnings per share basis. Horizon Pharma employs 1,010 workers across the globe.
How can I contact Horizon Pharma?
Horizon Pharma's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, DUBLIN L2, D04 C5Y6. The biopharmaceutical company can be reached via phone at 011-353-1772-2100 or via email at [email protected]
MarketBeat Community Rating for Horizon Pharma (HZNP)
MarketBeat's community ratings are surveys of what our community members think about Horizon Pharma and other stocks. Vote "Outperform" if you believe HZNP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HZNP will underperform the S&P 500 over the long term. You may vote once every thirty days.
Horizon Pharma (NASDAQ:HZNP) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
10 Wall Street analysts have issued ratings and price targets for Horizon Pharma in the last 12 months. Their average twelve-month price target is $19.20, suggesting that the stock has a possible upside of 25.00%. The high price target for HZNP is $24.00 and the low price target for HZNP is $16.00. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.90 | 2.91 | 2.92 | 2.83 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $19.20 | $18.6364 | $19.25 | $18.4167 |
| Price Target Upside: | 25.00% upside | 36.03% upside | 27.57% upside | 28.34% upside |
Horizon Pharma (NASDAQ:HZNP) Consensus Price Target History
Horizon Pharma (NASDAQ:HZNP) Analyst Ratings History
Show:
(Data available from 5/23/2016 forward)
Horizon Pharma (NASDAQ:HZNP) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Horizon Pharma (NASDAQ HZNP) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 3.90%
Institutional Ownership Percentage: 84.33%
Horizon Pharma (NASDAQ HZNP) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/10/2017 | Michael G Grey | Director | Buy | 10,000 | $9.48 | $94,800.00 | |  |
| 3/1/2017 | Robert Carey | EVP | Sell | 31,808 | $16.03 | $509,882.24 | | |
| 8/2/2016 | Jeffrey W. Sherman | EVP | Sell | 2,900 | $20.00 | $58,000.00 | | |
| 6/15/2016 | Virinder Nohria | Director | Sell | 25,000 | $17.69 | $442,250.00 | 189,836 | |
| 2/26/2016 | Jeffrey W Sherman | EVP | Sell | 4,100 | $20.00 | $82,000.00 | 149,648 | |
| 12/10/2015 | Jeffrey W Sherman | EVP | Sell | 4,456 | $20.00 | $89,120.00 | 105,132 | |
| 9/21/2015 | Jeffrey W Sherman | EVP | Sell | 7,750 | $31.78 | $246,295.00 | 105,132 | |
| 7/15/2015 | Jeffrey W Sherman | EVP | Sell | 26,887 | $35.55 | $955,832.85 | | |
| 3/13/2015 | Jeff Himawan | Director | Sell | 554,564 | $22.44 | $12,444,416.16 | | |
| 3/10/2015 | Jeff Himawan | Director | Sell | 1,614,827 | $21.85 | $35,283,969.95 | | |
| 11/19/2014 | Jeff Himawan | Director | Sell | 3,450,000 | $12.05 | $41,572,500.00 | | |
| 11/19/2014 | Jeffrey W Sherman | EVP | Sell | 24,999 | $12.05 | $301,237.95 | | |
| 11/19/2014 | Timothy P Walbert | CEO | Sell | 150,000 | $12.05 | $1,807,500.00 | | |
| 11/13/2014 | Balaji Venkataraman | Major Shareholder | Sell | 6,086,957 | $11.54 | $70,243,483.78 | | |
| 11/13/2014 | Virinder Nohria | Director | Sell | 1,739,130 | $11.54 | $20,069,560.20 | | |
| 9/30/2014 | Vaere Robert J De | CFO | Sell | 51,942 | $12.28 | $637,847.76 | | |
| 5/19/2014 | Timothy Walbert | CEO | Sell | 31,742 | $12.94 | $410,741.48 | 148,930 | |
| 5/19/2014 | Todd Smith | EVP | Sell | 10,159 | $12.94 | $131,457.46 | 44,552 | |
| 5/19/2014 | Vaere Robert De | CFO | Sell | 12,939 | $12.94 | $167,430.66 | 88,555 | |
| 12/13/2013 | Jeffrey Bird | Director | Buy | 668,673 | $6.50 | $4,346,374.50 | 5,000 | |
| 12/9/2013 | Timothy Walbert | CEO | Sell | 12,124 | $6.79 | $82,321.96 | 148,497 | |
| 12/9/2013 | Todd Smith | EVP | Sell | 11,322 | $6.91 | $78,235.02 | 40,961 | |
| 11/21/2013 | Jeffrey Bird | Director | Buy | 151,089 | $6.24 | $942,795.36 | 5,000 | |
| 9/25/2012 | Jeffrey W Bird | Director | Buy | 575,356 | $3.49 | $2,007,992.44 | | |
(Data available from 1/1/2013 forward)
Horizon Pharma (NASDAQ HZNP) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Brokerages Expect Horizon Pharma PLC (HZNP) Will Announce Quarterly Sales of $278.03 Million
www.americanbankingnews.com - May 23 at 3:36 AM |
 | Horizon Pharma plc Launches GoutRevealed.com to Spotlight the Journey and Stories of People Living with Uncontrolled Gout
finance.yahoo.com - May 22 at 5:10 PM |
 | Horizon Pharma (HZNP) Presents At 2018 UBS Global Healthcare Conference - Slideshow
seekingalpha.com - May 22 at 5:10 PM |
| Zacks: Brokerages Expect Horizon Pharma PLC (HZNP) Will Post Earnings of $0.33 Per Share
www.americanbankingnews.com - May 21 at 11:13 AM |
| Horizon Pharma (HZNP) Lifted to "Hold" at BidaskClub
www.americanbankingnews.com - May 16 at 11:05 AM |
| Phase two of clinical gout trial begins at UAB
finance.yahoo.com - May 14 at 5:22 PM |
| Q2 2018 EPS Estimates for Horizon Pharma Boosted by Analyst (HZNP)
www.americanbankingnews.com - May 14 at 2:18 AM |
 | Trump blames 'freeloading' foreign countries for high drug prices
www.ft.com - May 11 at 6:00 PM |
 | BRIEF-Horizon Pharma Q1 Non-Gaap Earnings Per Share $0.03
www.reuters.com - May 11 at 6:00 PM |
| Horizon Pharma plc 2018 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 11 at 6:00 PM |
| Equities Analysts Offer Predictions for Horizon Pharma's Q2 2018 Earnings (HZNP)
www.americanbankingnews.com - May 11 at 9:39 AM |
| Free Daily Technical Summary Reports on Horizon Pharma and Three More Generic Drugs Stocks
finance.yahoo.com - May 11 at 8:21 AM |
| Horizon Pharma (HZNP) Q1 Earnings & Sales Miss, Shares Fall
finance.yahoo.com - May 10 at 5:59 PM |
| Edited Transcript of HZNP earnings conference call or presentation 9-May-18 12:00pm GMT
finance.yahoo.com - May 10 at 8:20 AM |
| Horizon Pharma (HZNP) Given a $17.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - May 9 at 6:50 PM |
| Horizon Pharma Plc (HZNP) Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 5:36 PM |
| Horizon Pharma Q1 top line up 1%; non-GAAP earnings down 86%; guidance raised; operating structure revamped
seekingalpha.com - May 9 at 5:36 PM |
| Horizon Pharma (HZNP) Q1 Loss Wider, Revenues Miss
finance.yahoo.com - May 9 at 5:36 PM |
| Horizon Pharma (HZNP) Releases Earnings Results, Misses Expectations By $0.03 EPS
www.americanbankingnews.com - May 9 at 2:19 PM |
| Horizon Pharma Q1 revenues up 1%; raises guidance
seekingalpha.com - May 9 at 8:16 AM |
| Horizon Pharma misses by $0.04, misses on revenue
seekingalpha.com - May 9 at 8:16 AM |
| Horizon Pharma plc Reports Strong First-Quarter 2018 Orphan and Rheumatology Net Sales Growth; Increases Full-Year 2018 Guidance and Announces New Company Operating Structure to Enhance Focus on Rare Diseases
finance.yahoo.com - May 9 at 8:16 AM |
| Horizon Pharma: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 8:16 AM |
| Horizon Pharma nabs two U.S. patents covering Ravicti; shares up 2%
seekingalpha.com - May 8 at 5:41 PM |
| What Are Analysts Saying About Horizon Pharma Public Limited Company’s (NASDAQ:HZNP) Earnings Trajectory?
finance.yahoo.com - May 8 at 5:41 PM |
| Horizon Pharma (HZNP) Lifted to "Hold" at ValuEngine
www.americanbankingnews.com - May 8 at 3:49 PM |
| Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of Additional Notices of Allowance With Claims Covering RAVICTI® (glycerol phenylbutyrate) Oral Liquid
finance.yahoo.com - May 8 at 8:15 AM |
 | Interesting HZNP Put And Call Options For November 16th
www.nasdaq.com - May 7 at 5:40 PM |
| Mizuho Reaffirms "Buy" Rating for Horizon Pharma (HZNP)
www.americanbankingnews.com - May 7 at 4:27 PM |
 | What's in Store for Horizon Pharma (HZNP) in Q1 Earnings?
www.zacks.com - May 7 at 8:18 AM |
| $239.45 Million in Sales Expected for Horizon Pharma (HZNP) This Quarter
www.americanbankingnews.com - May 6 at 7:45 AM |
| Zacks Investment Research Downgrades Horizon Pharma (HZNP) to Hold
www.americanbankingnews.com - May 5 at 1:07 AM |
| $0.11 EPS Expected for Horizon Pharma (HZNP) This Quarter
www.americanbankingnews.com - May 4 at 3:20 AM |
| Horizon Pharma plc Announces Sangita Iyer as a 2018 Healthcare Businesswomen’s Association Rising Star
finance.yahoo.com - May 3 at 8:13 AM |
| ValuEngine Lowers Horizon Pharma (HZNP) to Sell
www.americanbankingnews.com - May 2 at 11:33 PM |
| Horizon Pharma (HZNP) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 2 at 4:16 AM |
| Horizon Pharma (HZNP) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 29 at 11:30 AM |
| Zacks.com highlights: Western Digital, ArcelorMittal, Arrow Electronics and Horizon Pharma Public
finance.yahoo.com - April 18 at 8:14 AM |
| Zacks: Analysts Anticipate Horizon Pharma PLC (HZNP) Will Announce Quarterly Sales of $245.18 Million
www.americanbankingnews.com - April 18 at 1:50 AM |
| Zacks: Analysts Expect Horizon Pharma PLC (HZNP) to Post $0.11 EPS
www.americanbankingnews.com - April 16 at 11:10 PM |
| Cantor Fitzgerald Analysts Give Horizon Pharma (HZNP) a $17.00 Price Target
www.americanbankingnews.com - April 16 at 7:39 AM |
| Cantor Fitzgerald Analysts Give Horizon Pharma (HZNP) a $13.00 Price Target
www.americanbankingnews.com - April 15 at 9:31 AM |
| Horizon Pharma (HZNP) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - April 14 at 10:53 PM |
| Horizon Pharma plc Named No. 1 Biopharma Company to Work for by Great Place to Work® and FORTUNE
finance.yahoo.com - April 12 at 5:40 PM |
| Horizon Pharma (HZNP) Receives "Neutral" Rating from Mizuho
www.americanbankingnews.com - April 11 at 11:52 PM |
| Horizon Pharma (HZNP) Receives Outperform Rating from BMO Capital Markets
www.americanbankingnews.com - April 11 at 5:35 PM |
| New Research: Key Drivers of Growth for Talend S.A, Chipmos Technologies, POSCO, Horizon Pharma Public, BioSpecifics Technologies, and Arbutus Biopharma — Factors of Influence, Major Initiatives and Sustained Production
finance.yahoo.com - April 11 at 8:28 AM |
| Horizon Pharma plc to Release First-Quarter 2018 Financial Results and Host Webcast on May 9, 2018
finance.yahoo.com - April 9 at 8:16 AM |
| Horizon Pharma (HZNP) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - April 7 at 4:58 PM |
| Piper Jaffray Analysts Give Horizon Pharma (HZNP) a $18.00 Price Target
www.americanbankingnews.com - April 7 at 12:30 PM |
Horizon Pharma (NASDAQ:HZNP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Horizon Pharma (NASDAQ:HZNP) Income Statement, Balance Sheet and Cash Flow Statement
Horizon Pharma (NASDAQ HZNP) Stock Chart for Wednesday, May, 23, 2018
Loading chart…
